Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh AD Immunotherapeutic Vaccine (UB-311)

Trial Profile

An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh AD Immunotherapeutic Vaccine (UB-311)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs UB 311 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors United Neuroscience
  • Most Recent Events

    • 21 Jan 2019 Planned End Date changed from 1 Dec 2020 to 1 Mar 2021.
    • 21 Jan 2019 Planned primary completion date changed from 1 Nov 2020 to 1 Mar 2021.
    • 10 Sep 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top